Navigation Links
New Brunswick Scientific Completes Merger Transaction with Eppendorf
Date:9/24/2007

EDISON, N.J., Sept. 24 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. ("NBS") (Nasdaq: NBSC), and Eppendorf Group ("Eppendorf") announced today the completion of the previously announced merger transaction in which Eppendorf acquired NBS for approximately $110 million in an all-cash transaction. As a result of the merger, which was approved by NBS' shareholders at a special meeting on September 20, 2007, NBS' shareholders are entitled to receive $11.50 per share in cash.

NBS has notified the NASDAQ Global Market of the closing of the transaction and expects that no further trading in NBS stock will occur after today and that its shares will no longer be listed. Eppendorf has appointed American Stock Transfer & Trust Company as paying agent, and, will promptly mail a letter of transmittal and instructions to all NBS shareholders of record. The letter of transmittal and instructions will contain information on how to surrender stock certificates representing shares of NBS common stock in exchange for $11.50 per share, without interest. NBS' shareholders of record should wait until they receive the letter of transmittal before surrendering their stock certificates. Shareholders who hold shares through a bank or broker will not have to take any action to have their shares exchanged for the merger consideration as such exchanges will be handled by the bank or broker.

About New Brunswick Scientific

New Brunswick Scientific Co., Inc., is a leading global innovator providing a comprehensive line of equipment and instrumentation for the life science industry. NBS's products are used in the creation, maintenance and control of physical and biochemical environments required for the growth, detecti
'/>"/>

SOURCE New Brunswick Scientific Co., Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. UW-Madisons Beebe wins scientific award
2. Researchers say scientific reporting needs more perspective, less hype
3. Wisconsin stands at the center of scientific efforts to avert flu epidemics
4. Growth prompts new location for scientific instrument manufacturer
5. UW stem cell guru outlines scientific and political future
6. Wisconsin biotech sector featured in scientific magazine
7. Scientific Protein Laboratories Acquired by New York firm
8. GenTel Appoints Burke to its Scientific Advisory Board
9. Sonic Foundry completes $11.25M stock offer
10. Orion Energy completes $5M capital round
11. RedPrairie completes MARC acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
(Date:8/26/2015)... -- The Diabetes Research Institute (DRI), a Center of ... of Medicine, announced today that the first patient ... first time a novel transplant technique for insulin-producing ... I/II study builds upon decades of progress in ... step toward the development of the DRI BioHub, ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation ... announced today the closing of its previously announced public ... by the underwriters of their option to purchase an ... offering price of $41.00 per share.  The exercise of ... of common stock sold by Intrexon to 5,609,756 shares ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... ("MO2"), an entity wholly owned by Mr. Yuen Kam, ... has acquired the outstanding shares (the "Shares") of  Excellent ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... December - - PC-Insulin Preclinical Study Results ... Biotechnologies,Inc. (TSX:CJB) announced today that dosing is complete ... Phase II trial was a,randomized, double-blind, placebo-controlled, multiple ... three months of weekly injections of,PC-DAC(TM):Exendin-4 in patients ...
... NOVATO, Calif., Nov. 5 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Credit ... November 12, 2008 at 10:30 a.m. MST., Interested ... conference,call via the investor section of the BioMarin website, ...
... DIEGO, Nov. 5 Ambrx Inc. today announced ... clinical trial of ARX201,the company,s long-acting human growth ... at the International Congress of,Endocrinology meeting in Rio ... and Vice President of Academic Affairs at Stanford ...
Cached Biology Technology:ConjuChem Provides Development Update 2ConjuChem Provides Development Update 3BioMarin to Present at the Credit Suisse Healthcare Conference 2Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... ELISA Development kit contains the basic components ... to measure natural and recombinant Feline IL-10 ... kit contains sufficient materials to run ELISAs ... the following conditions are met: The ...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: